Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

xantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the failure of pixantrone to have a low cardiotoxicity profile or to produce low cardiac toxicity, the failure of pixantrone to produce high rates of overall response including high rates of complete responses , the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100

    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015  NanoSmart ... drug delivery platforms, has received Orphan Drug Designation ... a second drug product that uses NanoSmart,s proprietary ... formulation of dactinomycin for the treatment of Ewing,s ... The FDA granted NanoSmart,s Orphan Drug Designation on ...
(Date:7/30/2015)...  Cleave Biosciences today announced that the United ... company a key patent providing the protection of ... This newly issued patent, "Fused pyrimidines and ... allows for claims on the composition of matter ... of p97, a critical enzyme that controls various ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
... , MOUNTAIN VIEW, Calif., Dec. 18 ... of Ruediger Naumann-Etienne to its Board of Directors. , "Rudi ... medical device companies," said Theodore A. Boutacoff, President and CEO ... & Quist followed by CEO/President positions with Diasonics, OEC Medical ...
... Dec. 18 Eli Lilly and Company (NYSE: ... and chief financial officer for Lilly, has assumed expanded responsibilities ... and chief financial officer, effective January 1. , In ... officer of the company and add responsibility for global services, ...
Cached Medicine Technology:Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 2Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 3Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2
(Date:7/30/2015)... ... 30, 2015 , ... Boston Web Marketing is ... Google Partners is the platform for search marketing agencies to communicate with the ... necessary to run successful search marketing campaigns. Google Partners also affords businesses the ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ocean Hills Recovery has officially been accredited ... “no recommendations.” No recommendations means CARF found no areas in the OHR program that ... than 3% of all facilities receive. In addition, Ocean Hills was granted the maximum ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... National Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn ... (NCI)-designated cancer center. TCI joins an elite group of 69 cancer institutions nationwide ...
(Date:7/30/2015)... ... 30, 2015 , ... 1Heart Caregiver Services LLC is offering its 1st Business ... in the Booming Homecare Business.” This will be held in its main headquarters at ... event will be hosted by 1Heart’s very own Randy Clarito (Director of Business and ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Summer is ... hot spots.”* Add to that a particularly long, dry and hot 2015 summer season ... host and fresh water advocate Sharon Kleyne will discuss the 2015 summer season and ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... at the Medical Research Council have identified changes in ... in the esophagus, a condition called Barrett,s dysplasia, making ... before they develop into esophageal cancer. These findings, reported ... implications for patients and may help to monitor their ...
... new technology developed by neuroscientists at Cold Spring Harbor Laboratory ... made of whole brains. Until now, means of obtaining ... mammalian brain -- have been painstakingly slow and available only ... By automating and standardizing the process in which brain samples ...
... (HealthDay News) -- When women seem scarce, men may compete ... according to a new study. "What we see in ... more competitive. They compete more for access to mates," lead ... Carlson School of Management at the University of Minnesota, said ...
... FRIDAY, Jan. 13 (HealthDay News) -- Health and fitness experts ... by flogging long-range benefits such as losing weight or avoiding ... been going about it all wrong. Research now appears to ... effective message than "feel better now." A University of ...
... indices to identify patients with symptoms associated with ovarian cancer who ... the US in an attempt to promote earlier diagnosis, but they ... cancer, according to a study published January 13 in the ... cancer is a disease which is perceived to rarely produce symptoms ...
... wearing contact lenses affects glaucoma measurements has been named ... of Medicine,s annual St. Albert,s Day research symposium. ... fourth-year student at Stritch School of Medicine. Brenner ... on retinal nerve fiber layer measurements, which ophthalmologists use ...
Cached Medicine News:Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts 2Health News:CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts 3Health News:Do Men Flash Cash to Find a Mate? 2Health News:Need to Exercise More? Think How It Will Help You Now 2Health News:Need to Exercise More? Think How It Will Help You Now 3Health News:Predicting the value of indexing symptoms for ovarian cancer 2
... Eliminate the need for makeshift, modified ... Why waste time gathering parts when your ... need to deliver the utmost in Heliox ... therapy is fast becoming the standard of ...
... has been developing diverse medical ... years. Our medical-surgical products have ... innovation, quality and customer satisfaction. ... the Labtron® line of diagnostic ...
... nebulizer utilizing Vibrating Mesh Technology to ... suffering from Asthma, COPD or other ... product size and handy carrying case ... takes them. Powerful delivery comparable to ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
Medicine Products: